285 related articles for article (PubMed ID: 33583217)
1. Twenty-five years of triptans - a nationwide population study.
Davidsson OB; Olofsson IA; Kogelman LJ; Andersen MA; Rostgaard K; Hjalgrim H; Olesen J; Hansen TF
Cephalalgia; 2021 Jul; 41(8):894-904. PubMed ID: 33583217
[TBL] [Abstract][Full Text] [Related]
2. Impact of NSAID and Triptan use on developing chronic migraine: results from the American Migraine Prevalence and Prevention (AMPP) study.
Lipton RB; Serrano D; Nicholson RA; Buse DC; Runken MC; Reed ML
Headache; 2013; 53(10):1548-63. PubMed ID: 23992516
[TBL] [Abstract][Full Text] [Related]
3. Patterns of use of triptans and reasons for switching them in a tertiary care migraine population.
Sheftell FD; Feleppa M; Tepper SJ; Volcy M; Rapoport AM; Bigal ME
Headache; 2004; 44(7):661-8. PubMed ID: 15209687
[TBL] [Abstract][Full Text] [Related]
4. Hair analysis for detection of triptans occasionally used or overused by migraine patients-a pilot study.
Ferrari A; Baraldi C; Licata M; Vandelli D; Marchesi F; Palazzoli F; Verri P; Rustichelli C; Giuliani E; Silingardi E
Eur J Clin Pharmacol; 2016 Sep; 72(9):1075-81. PubMed ID: 27245458
[TBL] [Abstract][Full Text] [Related]
5. Low adherence to the guideline for the acute treatment of migraine.
Olesen A; Schytz HW; Ostrowski SR; Topholm M; Nielsen K; Erikstrup C; Mikkelsen S; Pedersen OB; Olesen J; Hansen TF; Chalmer MA
Sci Rep; 2022 May; 12(1):8487. PubMed ID: 35589944
[TBL] [Abstract][Full Text] [Related]
6. Rizatriptan: a pharmacoeconomic review of its use in the acute treatment of migraine.
McCormack PL; Foster RH
Pharmacoeconomics; 2005; 23(12):1283-98. PubMed ID: 16336021
[TBL] [Abstract][Full Text] [Related]
7. Triptans in the Acute Treatment of Migraine: A Systematic Review and Network Meta-Analysis.
Cameron C; Kelly S; Hsieh SC; Murphy M; Chen L; Kotb A; Peterson J; Coyle D; Skidmore B; Gomes T; Clifford T; Wells G
Headache; 2015; 55 Suppl 4():221-35. PubMed ID: 26178694
[TBL] [Abstract][Full Text] [Related]
8. Triptan non-response in specialized headache care: cross-sectional data from the DMKG Headache Registry.
Ruscheweyh R; Gossrau G; Dresler T; Freilinger T; Förderreuther S; Gaul C; Kraya T; Neeb L; Ruschil V; Straube A; Scheidt J; Jürgens TP
J Headache Pain; 2023 Oct; 24(1):135. PubMed ID: 37817093
[TBL] [Abstract][Full Text] [Related]
9. The use of triptans for pediatric migraines.
Eiland LS; Hunt MO
Paediatr Drugs; 2010 Dec; 12(6):379-89. PubMed ID: 21028917
[TBL] [Abstract][Full Text] [Related]
10. Comparative efficacy of triptans for the abortive treatment of migraine: a multiple treatment comparison meta-analysis.
Thorlund K; Mills EJ; Wu P; Ramos E; Chatterjee A; Druyts E; Goadsby PJ
Cephalalgia; 2014 Apr; 34(4):258-67. PubMed ID: 24108308
[TBL] [Abstract][Full Text] [Related]
11. Economic analysis of triptan therapy for acute migraine: a Medicaid perspective.
Mullins CD; Subedi PR; Healey PJ; Sanchez RJ
Pharmacotherapy; 2007 Aug; 27(8):1092-101. PubMed ID: 17655509
[TBL] [Abstract][Full Text] [Related]
12. Use of the sustained pain-free plus no adverse events endpoint in clinical trials of triptans in acute migraine.
Dodick DW; Sandrini G; Williams P
CNS Drugs; 2007; 21(1):73-82. PubMed ID: 17190530
[TBL] [Abstract][Full Text] [Related]
13. The 5-HT
Whealy M; Becker WJ
Handb Clin Neurol; 2024; 199():17-42. PubMed ID: 38307644
[TBL] [Abstract][Full Text] [Related]
14. Triptans (serotonin, 5-HT1B/1D agonists) in migraine: detailed results and methods of a meta-analysis of 53 trials.
Ferrari MD; Goadsby PJ; Roon KI; Lipton RB
Cephalalgia; 2002 Oct; 22(8):633-58. PubMed ID: 12383060
[TBL] [Abstract][Full Text] [Related]
15. Triptan use in Australia 1997-2015: A pharmacoepidemiological study.
Eyre BLKD; Eadie MJ; van Driel ML; Ross-Lee L; Hollingworth SA
Acta Neurol Scand; 2017 Aug; 136(2):155-159. PubMed ID: 28093722
[TBL] [Abstract][Full Text] [Related]
16. [Clinical use of triptans in the management of migraine].
Lantéri-Minet M
CNS Drugs; 2006; 20 Spec no.1():12-23. PubMed ID: 16841523
[TBL] [Abstract][Full Text] [Related]
17. Triptans for the management of migraine.
Johnston MM; Rapoport AM
Drugs; 2010 Aug; 70(12):1505-18. PubMed ID: 20687618
[TBL] [Abstract][Full Text] [Related]
18. Triptan overuse in the Dutch general population: a nationwide pharmaco-epidemiology database analysis in 6.7 million people.
Dekker F; Wiendels NJ; de Valk V; van der Vliet C; Knuistingh Neven A; Assendelft WJ; Ferrari MD
Cephalalgia; 2011 Jun; 31(8):943-52. PubMed ID: 21593190
[TBL] [Abstract][Full Text] [Related]
19. Triptans in migraine: a comparative review of pharmacology, pharmacokinetics and efficacy.
Tfelt-Hansen P; De Vries P; Saxena PR
Drugs; 2000 Dec; 60(6):1259-87. PubMed ID: 11152011
[TBL] [Abstract][Full Text] [Related]
20. Identifying the factors underlying discontinuation of triptans.
Wells RE; Markowitz SY; Baron EP; Hentz JG; Kalidas K; Mathew PG; Halker R; Dodick DW; Schwedt TJ
Headache; 2014 Feb; 54(2):278-89. PubMed ID: 24001117
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
